The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema

The following is an abbreviated list of inclusion criteria: * Adults between 18 to 80 years of age, inclusive * Diagnosis of diabetes mellitus (type 1 or type 2) * Decrease in vision in the study eye determined to be primarily the result of DME * Definite retinal thickening due to diffuse DME involving the central macula in the study eye * Central subfield thickness of at least 325 µm by sdOCT with presence of intraretinal fluid in the study eye * ETDRS BCVA letter score ≤ 76 and ≥ 24 in the study eye The following is an abbreviated list of exclusion criteria: * Hemoglobin A1C (HbA1C) ≥ 12.0% at Screening * History of non infectious uveitis * Decrease in visual acuity due to causes other than DME in the study eye * History of any of the following in the study eye (however, the following are not exclusionary in the fellow eye): 1. Prior pars plana vitrectomy 2. Any ocular surgery within 3 months prior to Day 1 3. YAG capsulotomy within 3 months prior to Day 1 4. Panretinal scatter photocoagulation (PRP) or focal laser within 3 months prior to Day 1 or anticipated need for PRP during the course of the study 5. Prior intravitreal, subtenon, or periocular steroid therapy within 3 months prior to Day 1 6. Prior treatment with intravitreal anti-vascular endothelial growth factor (VEGF) treatment within 8 weeks prior to Day 1